|
[1]
|
Castleman, B., Iverson, L. and Menendez, V.P. (1956) Localized Mediastinal Lymph-Node Hyperplasia Resembling Thymoma. Cancer, 9, 822-830. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
贾鸣男, 张路, 李剑. 特发性多中心型Castleman病的诊疗进展[J]. 中国肿瘤临床, 2019, 46(11): 541-545.
|
|
[3]
|
中华医学会血液学分会淋巴细胞疾病学组, 中国抗癌协会血液肿瘤专业委员会, 中国Castleman病协作组. 中国Castleman病诊断与治疗专家共识(2021年版) [J]. 中华血液学杂志, 2021, 42(7): 529-534.
|
|
[4]
|
Van Rhee, F., Oksenhendler, E., Srkalovic, G., Voorhees, P., Lim, M., Dispenzieri, A., et al. (2020) International Evidence-Based Consensus Diagnostic and Treatment Guidelines for Unicentric Castleman Disease. Blood Advances, 4, 6039-6050. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Alaggio, R., et al. (2022) The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 36, 1720-1748.
|
|
[6]
|
李理, 张蕊, 王天有. Castleman病的发病机制及治疗研究进展[J]. 中国小儿血液与肿瘤杂志, 2022, 27(5): 336-339+348.
|
|
[7]
|
Dispenzieri, A., Armitage, J.O., Loe, M.J., Geyer, S.M., Allred, J., Camoriano, J.K., et al. (2012) The Clinical Spectrum of Castleman’s Disease. American Journal of Hematology, 87, 997-1002. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
刘秀芬, 马静, 周丽娟, 等. Castleman病最新研究进展[J]. 中国医学文摘(耳鼻咽喉科学), 2019, 34(5): 360-363.
|
|
[9]
|
王艳龙, 徐钰欣, 孙象军. 腹膜后Castleman病10例临床与病理特征分析[J]. 中国现代普通外科进展, 2024, 27(4): 305-308.
|
|
[10]
|
Fajgenbaum, D.C., van Rhee, F. and Nabel, C.S. (2014) HHV-8-Negative, Idiopathic Multicentric Castleman Disease: Novel Insights into Biology, Pathogenesis, and Therapy. Blood, 123, 2924-2933. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Gagliardo, C., Johnson, E. and Di Pentima, M.C. (2021) Leuconostoc lactis Sepsis in a Child with Chromosomal 18 Abnormality Receiving Enteral Nutrition. Journal of Paediatrics and Child Health, 57, 170. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Karaca, F., Usul Afşar, Ç., Erkurt, E., Arslantaş, H.S., Çalış, E., Totan Ateş, B., et al. (2014) The Role of Radiotherapy among the Therapeutic Options for Castleman’s Disease. Turkish Journal of Hematology, 31, 197. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Rose-John, S. (2012) IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of Il-6. International Journal of Biological Sciences, 8, 1237-1247. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
徐傲, 陈柯, 王琦, 等. Castleman病45例临床病理学分析[J]. 安徽医药, 2017, 21(9): 1632-1637.
|
|
[15]
|
刘琰婷. Castleman病的基础和临床研究[D]: [博士学位论文]. 北京: 北京协和医学院, 2025.
|
|
[16]
|
Liu, H.L., Fan, L. and Li, J.Y. (2020) Progress in the Diagnosis and Treatment of Castleman Disease. Chinese Journal of Tuberculosis and Respiratory Diseases, 41, 697-700.
|
|
[17]
|
Nishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N. and Kakehi, T. (2008) Mechanisms and Pathologic Significances in Increase in Serum Interleukin-6 (IL-6) and Soluble IL-6 Receptor after Administration of an Anti-IL-6 Receptor Antibody, Tocilizumab, in Patients with Rheumatoid Arthritis and Castleman Disease. Blood, 112, 3959-3964. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Mukherjee, S., Martin, R., Sande, B., Paige, J.S. and Fajgenbaum, D.C. (2022) Epidemiology and Treatment Patterns of Idiopathic Multicentric Castleman Disease in the Era of Il-6-Directed Therapy. Blood Advances, 6, 359-367. [Google Scholar] [CrossRef] [PubMed]
|